[ONTX] Onconova Therapeutics, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ONTX
ONTX is in the medium-term down -67% in 3 months and down -87% in 5 months and down -93% in 1 year. In the long-term down -95% in 2 years and up 30069% in 21 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -8.8% | Sales Growth - Q/Q | 0% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -156.2% | ROE | -487.72% | ROI | ||
| Current Ratio | 3.38 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.92 | ||
| Gross Margin | Operating Margin | -12282.7% | Net Profit Margin | -12279.7% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | -9.85 M | Gross Profit | |||
| Net Profit | -12.34 M | Operating Profit | -12.35 M | Total Assets | 36.71 M | Total Current Assets | 36.35 M |
| Total Current Liabilities | 10.76 M | Total Debt | Total Liabilities | 24.95 M | Total Revenue | 110 K |
Technical Data
| High 52 week | 5.78 | Low 52 week | 0.3 | Last close | 0.3 | Last change | -24.58% |
| RSI | 26.62 | Average true range | 0.06 | Beta | 0.13 | Volume | 18.76 K |
| Simple moving average 20 days | -37.42% | Simple moving average 50 days | -66.09% | Simple moving average 200 days | -88.69% |
Performance Data
| Performance Week | -16.19% | Performance Month | -64.92% | Performance Quart | -86.53% | Performance Half | -90.77% |
| Performance Year | -92.55% | Performance Year-to-date | -85.7% | Volatility daily | 10.4% | Volatility weekly | 23.26% |
| Volatility monthly | 47.67% | Volatility yearly | 165.14% | Relative Volume | 157.7% | Average Volume | 426.28 K |
| New High | New Low |
News
2020-01-03 13:27:41 | Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
2020-01-02 13:48:43 | Bucks County biopharm firm plans $10M stock sale
2019-12-31 11:30:10 | Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market
2019-12-23 19:33:30 | Onconova Therapeutics, Inc. ONTX Is Burning These Hedge Funds
2019-12-19 13:44:55 | Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
2019-12-18 09:05:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
2019-12-18 09:00:10 | Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand
2019-12-17 07:30:10 | Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil
2019-12-10 15:07:58 | Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
2019-12-09 08:00:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
2019-12-06 08:49:10 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIX
2019-12-06 07:30:10 | Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
2019-11-25 09:26:13 | Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
2019-11-22 14:46:50 | Bucks County biopharm firm enters into licensing deal, embarks on stock sale
2019-11-21 11:23:16 | Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering
2019-11-21 10:16:12 | Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada
2019-11-07 07:30:00 | Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes MDS at the ASH 2019 Annual Meeting & Exposition
2019-10-24 07:30:05 | Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
2019-09-24 10:15:50 | Bucks County biopharm firm opts for private over public stock sale
2019-09-23 08:52:19 | Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
2019-09-19 07:39:31 | The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO
2019-09-18 10:05:00 | Onconova Therapeutics Announces Termination of Proposed Public Offering
2019-09-16 07:30:00 | Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
2019-08-16 17:26:25 | Edited Transcript of ONTX earnings conference call or presentation 14-Aug-19 1:00pm GMT
2019-08-14 07:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results
2019-08-12 07:30:00 | Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics
2019-08-07 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results
2019-08-06 10:30:02 | Onconova Therapeutics ONTX May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2019-06-10 07:30:00 | Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association
2019-05-28 07:30:00 | Onconova Therapeutics Announces Presentations at Three Upcoming Conferences
2019-05-14 18:23:32 | Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT
2019-05-14 07:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results
2019-05-13 12:52:11 | Newtown biopharm firm could reap $50M from Chinese licensing deal
2019-05-13 07:30:00 | Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China
2019-05-07 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results
2019-05-06 07:30:00 | Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes MDS 2019 in Copenhagen, Denmark
2019-04-02 07:30:00 | Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9
2019-03-26 15:59:57 | Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT
2019-03-26 07:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results
2019-03-25 07:30:00 | Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes
2019-03-19 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results
2019-03-12 07:30:00 | Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA
2019-02-04 08:00:00 | Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
2019-01-31 07:30:00 | Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
2019-01-22 07:30:00 | Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
2019-01-16 13:08:04 | Bucks County biopharm firm names new CEO
2019-01-15 17:15:00 | Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
2019-01-02 07:30:00 | Onconova Submits Special Protocol Assessment SPA to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine Vidaza® for First-Line Myelodysplastic Syndromes MDS